The approvals allow the company to offer its PCR-based expression profile cancer risk tests in the state.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.
The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.
The financing will go toward commercial and clinical activities to increase adoption of the company's DecisionDx-Melanoma test.
The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.
Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.
The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.
Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.
In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.